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For maximal public health impact, staff from the disciplines of program and science need to 
closely work together. For this commentary, we define program as work that builds and 
maintains a public health infrastructure with policies, plans, and capacity for the provision of 
essential services and interventions.1–4 We define science as work that is based on 
standardized methods of information collection, data management and analysis, continuous 
quality improvement,5–7 and information dissemination that includes the domains of 
surveillance,8 epidemiology,9 evaluation,10 and economics.11 Two recent strategies in the 
field of human immunodeficiency virus (HIV)/sexually transmitted infections are helping 
improve the integration of program and science with science-led activities.12–15 In this 
commentary, we summarize results from the use of a different strategy, which integrates 
program and science with program-led activities.
As part of a new funding cycle that began in January 2012, the Centers for Disease Control 
and Prevention (CDC) established cooperative agreements with 61 health departments under 
Funding Opportunity Announcement (FOA) PS12-1201 to conduct comprehensive routine 
HIV prevention services (known as Category A), which included HIV testing, partner 
services, and linkage and reengagement to HIV medical care.1 In March 2012 under this 
same FOA, CDC awarded 30 of the 61 health departments competitive funding to conduct 
their own high-impact HIV prevention16 nonresearch demonstration projects (known as 
Category C) that had to be consistent with the 2010–2015 National HIV/AIDS Strategy 
(NHAS).17 Category C projects were funded for four years through December 2015 and 
conducted by health departments (24 state, 2 county, and 4 city) in all U.S. Census Bureau 
regions.
Main outcomes desired from Category C projects included high-impact work and successful 
work transferred to routine public health practice after the end of Category C funding. 
Projects involved program and science experts who worked closely together at the local and 
national levels. Of the 30 health departments, 21 collaborated with universities and 21 
collaborated with community-based organizations.
Correspondence: John Beltrami, MD, MPH&TM, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for 
Disease Control and Prevention, 1600 Clifton Rd, NE, Atlanta, GA 30333 (hzb3@cdc.gov). 
The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for 
Disease Control and Prevention.
None of the authors have any conflicts or possible conflicts of interest, and no funding was given for the work of the authors.
HHS Public Access
Author manuscript
J Public Health Manag Pract. Author manuscript; available in PMC 2018 November 01.
Published in final edited form as:
J Public Health Manag Pract. 2017 ; 23(6): 560–563. doi:10.1097/PHH.0000000000000585.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Primary sources of information used for this commentary included health department 
applications; semiannual progress reports; final reports; and records from conference calls, 
e-mails, and site visits. Health departments were required to conduct project activities in at 
least one of 5 focus areas. The 30 funded health departments conducted activities in the 
following focus areas: HIV testing (19 health departments), engagement in HIV care (25 
health departments), use of HIV surveillance data for programmatic purposes (25 health 
departments), structural, behavioral, or biomedical interventions (10 health departments), 
and use of advanced technology (8 health departments). Because each intervention and 
advanced technology activity was unique, aggregating results from these projects was not 
possible. Thus, results from these 2 focus areas are not included in this commentary.
To help determine whether the projects were successful in aggregate from a CDC 
perspective, CDC scientists with expertise in research, evaluation, and program 
implementation were consulted. Because Category C projects were not research and did not 
benefit from controlled comparison groups, standardized methodologies across health 
departments, pre-/postmethodological designs, or the ability to confirm new HIV diagnoses 
for all testing, alternative approaches to determine success were discussed. Two types of 
comparisons of quantitative results were used: 1) compare Category C results with Category 
A results and 2) compare Category C results with a relevant standard (e.g., CDC guidelines 
for HIV testing in healthcare settings18), NHAS goal, or FOA standard, and when no such 
comparisons were available, then findings from the published scientific literature.
HIV Testing
Of the 19 health departments funded to conduct HIV testing, 9 tested in health care sites and 
10 tested in non–health care sites (Table). During 2012–2015, the newly diagnosed HIV 
positivity at the 9 health care sites was 0.4% (155/34 605) (range, 0.0%–4.5%) compared 
with a 0.1% minimum of newly diagnosed persons screened in health care sites,18 which is 
the threshold recommended by CDC to conduct HIV testing in health care sites and 0.5%, 
which was the aggregate percentage of all 61 FOA PS12-1201 health departments that 
conducted routine testing in health care sites as part of Category A funding during the same 
time period. During 2012–2015, the newly diagnosed HIV positivity at the 10 non–health 
care sites was 0.9% (185/19 824) (range, 0.0%–4.7%) compared with the 1.0% Category A 
FOA standard and 0.8% Category A performance of all 61 FOA PS12-1201 health 
departments that conducted routine testing in non–health care sites during the same time 
period.
Of these 19 health departments, the most commonly reported example of how health 
departments benefited from HIV testing activities was improved collaborations and 
coordination between program and treatment staff (n = 4), and 16 have sustained activities 
since Category C ended by using alternative funding sources.
Engagement in HIV Care
Eighteen health departments conducted linkage to HIV care (Table), which was defined as a 
patient who attended an appointment with an HIV medical provider within 90 days of an 
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HIV diagnosis. Linkage for these health departments during 2012–2015 was 87% 
(1987/2271) compared with the 85% NHAS goal, 80% Category A FOA standard, and 63%, 
which was the aggregate percentage of all 61 FOA PS12-1201 health departments that 
conducted linkage as part of Category A funding during 2013–2015 (only time period 
comparison data available). Twenty health departments conducted reengagement to HIV 
care for persons living with HIV who were never in care or who had fallen out of care.17 
Reengagement for these health departments during 2012–2015 was 75% (1485/1987) 
compared with 69%, which was the aggregate percentage of all 61 FOA PS12-1201 health 
departments that conducted reengagement activities as part of Category A funding during 
2015 (only time period comparison data available). Both NHAS and the FOA did not have a 
goal or standard for reengagement.
Of the 25 health departments funded for engagement in care, the most commonly reported 
example of how health departments benefited from these activities was improved 
collaborations and coordination between program and treatment staff (n = 14), and 20 have 
sustained activities since Category C funding ended by using alternative funding sources.
HIV Surveillance
The 25 health departments that were funded to use HIV surveillance data for programmatic 
purposes conducted 54 activities: monitoring and evaluation (n = 18), engagement in care (n 
= 13) (for which results are included earlier), partner services (n = 6), geo-mapping (n = 6), 
database merging/warehousing (n =5), interventions (n =4), and improving HIV case 
reporting (n = 2). Of the 6 health departments that used HIV surveillance data to document 
outcomes of HIV partner services, 14% (179/1294) of the partners of HIV-infected persons 
were newly diagnosed with HIV compared with 6% to 14% from other studies that 
conducted partner services.19–23 Of these 6 health departments, 2 focused their Category C 
activities on the statewide use of HIV surveillance data for partner services and achieved a 
confirmed newly diagnosed HIV positivity of 18% (78/427).
Of these 25 health departments, the 2 most commonly reported examples of how health 
departments benefited from the use of HIV surveillance data were improved collaborations 
and coordination among surveillance, program, and treatment staff (n = 12) and more 
accurate HIV surveillance data due to updates (eg, current locating information and risk 
factors of the persons who were reported to the HIV surveillance system) provided by 
program and treatment staff (n = 11). Twenty-one health departments have sustained 
activities since Category C funding ended by using alternative funding sources.
Conclusion and Implications
We consider many of the methods and results of these program-led program-science 
demonstration projects successful, primarily because of the multidisciplinary collaboration 
among surveillance, program, and treatment staff. For example, Category C activities that 
linked newly diagnosed persons to HIV care and used HIV surveillance data for partner 
services exceeded results of routine work that was conducted by health departments,24 
national standards and goals,1,17,18 and results from the literature.19–23 In addition to the 
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aforementioned high-impact quantitative results, health departments benefited by having 
enhanced local collaborations and improved surveillance data, and nearly all health 
departments have sustained part or all of their Category C activities since the ending of 
Category C funding.
Too often, health departments wait years for a successful research study to be completed and 
published and then hope that the methods are suitable for program implementation, which 
does not always occur.25 The Category C health department HIV prevention model has an 
important advantage compared with research. For findings that a health department 
considers successful or promising, policy and day-to-day practice can be readily changed. 
This occurred with most of the Category C activities because program-led program-science 
projects are focused on providing services to clients in a “real-world” setting and because 
the program staff funding the projects are usually the staff responsible for policy and 
practice. In sum, quicker and more relevant public health impact is obtained with the 
Category C health department HIV prevention model. The responsibility for the program 
staff is to stay engaged with scientists and a continuous quality improvement mind-set, 
because there will always be opportunities to further enhance public health impact from 
research and continuous quality improvement activities.5–7
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